research Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Cetuximab often causes skin problems, but they can be managed without stopping treatment.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Bilateral Trichotillomania of Eyelashes Triggered by Anxiety due to Nocturnal Enuresis: A Case Report
Anxiety from bedwetting caused a boy to pull out his eyelashes, but it was resolved with family and school support.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.
research A New Clinical Variant of Hereditary Localized Alopecia: Report of a Chinese Family Mapped to Chromosome 2p25.1–2p23.2
A new type of hereditary hair loss in a Chinese family is linked to chromosome 2p25.1–2p23.2.
research Hair transplantation. 3rd ed.
The book is an updated guide on hair transplant techniques, useful for beginners and professionals.
research 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia is a hair loss condition mainly affecting postmenopausal women, with unclear causes and various clinical patterns.
research Frontal fibrosing alopecia presenting with rapidly spreading facial papules in a premenopausal woman: Case report and review
A young woman developed facial bumps before hair loss, which is unusual for her condition.
research Answer
Cyclosporine-A can cause excessive hair growth, which usually stops after discontinuing the drug.
research Recent Progress in Prostaglandin F 2a Ethanolamide (Prostamide F2a) Research and Therapeutics
Bimatoprost treats glaucoma and promotes hair growth, with potential for more medical uses.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy
Facial hair loss and psychosocial issues are crucial in deciding treatment for alopecia areata.
research Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research [[Translated article]]Low-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series
Low-dose oral minoxidil can help improve hair and eyebrow growth in people with frontal fibrosing alopecia.
research Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA
Alopecia areata severity and symptoms vary by race and ethnicity.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Depression among Alopecia Areata Patients: Prevalence and associated factors in a Tunisian sample
Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research 50524 Facebook groups provide support and product recommendations for patients using scalp cooling to prevent chemotherapy-induced alopecia: A survey study
Facebook groups play a crucial role in supporting and guiding patients on scalp cooling and hair loss during chemotherapy.
research The fate of non-scalp hair in alopecia areata universalis under baricitinib treatment: A real-world single-center experience
Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
research 131 Patient experiences with alopecia areata: Sentiment analysis of survey responses
Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.
research Ciliary Madarosis Secondary to Intra-Arterial Chemotherapy for Retinoblastoma Treatment
Eyelash loss can temporarily occur from chemotherapy for retinoblastoma.
research Ayurvedic Management of Pakshmashata (Madarosis): A Case Report
Ayurvedic treatment helped a woman regrow her lost eyebrow and eyelash hair.
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research Unilateral Ciliary Madarosis in a Child After Coronavirus Disease 2019 (COVID-19) Infection
A child lost eyelashes on one eyelid after COVID-19, likely due to a temporary hair loss condition.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.